MedTrace Logo

Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

NCT00734045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2008-12-10

No results posted yet for this study

Summary

The primary objective of the study is to establish the correlation between NT-proBNP measurements in fresh human whole blood samples and those in plasma samples from the same study subjects, where said samples are collected in EDTA and Li-Hep anticoagulant tubes and measured by the StatusFirst™ CHF NT-proBNP device in conjunction with the DXpressTM Reader in a laboratory setting.

Conditions

  • Congestive Heart Failure (CHF)

Sponsors & Collaborators

  • Nanogen, Inc.

    lead INDUSTRY

Principal Investigators

  • Alan Wu, PhD · University of California San Francisco and San Francisco General Hospital

  • Alan Maisel, MD · University of California San Diego; Veteran's Affairs

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00734045 on ClinicalTrials.gov